Sermorelin

Geref · GRF 1-29

Growth HormoneNot ApprovedApprovedResearchSubQ

Popular for:Growth hormone stimulation, sleep quality, anti-aging

27

Registered Trials

0

Trial Publications

22

PubMed References

Approved

Evidence Level

Overview

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. The short version: people usually care about it for growth hormone stimulation, sleep quality, anti-aging, but the strength of the evidence depends heavily on indication and study type.

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), consisting of the first 29 amino acids of the 44-amino acid GHRH sequence. It was FDA-approved in 1997 as Geref for diagnostic evaluation of pituitary function and was used clinically for growth hormone deficiency in children.

Although the branded product was discontinued in 2008 due to manufacturing issues (not safety concerns), Sermorelin continues to be widely compounded and studied. It stimulates the pituitary to produce and release its own growth hormone, preserving the natural feedback loop.

Research Snapshot

What the evidence says

Approved

Sermorelin currently shows 27 registered trials from ClinicalTrials.gov, 0 PubMed trial publications (0 RCT-tagged), and 22 PubMed references matching the stored source query. Treat PubMed references as literature surface area, not a count of clinical trials.

Known vs uncertain

Known signals

  • 27 registered trials are tracked from ClinicalTrials.gov intervention records.
  • 0 PubMed clinical-trial publications are indexed.
  • 0 PubMed randomized controlled trial publications are indexed.
  • 22 PubMed references are tracked separately from trial counts and can include animal, in-vitro, review, mechanism, or clinical records.

Open questions

  • Evidence strength may vary by indication, route, formulation, and population.
  • Public anecdotes can highlight interest or concern but do not establish clinical efficacy.
  • Regulatory status and compounding access can change independently from the research literature.

Mechanism of Action

Sermorelin binds to GHRH receptors on somatotroph cells in the anterior pituitary, stimulating the synthesis and secretion of endogenous growth hormone.

Key Research Benefits

Stimulates natural GH production via pituitary
Preserves hypothalamic-pituitary feedback regulation
Studied for improved sleep quality (increased slow-wave sleep)
Researched for body composition improvements
Previously FDA-approved (Geref) — established safety profile

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

27

Registered Trials

0

Trial Publications

0

RCT Publications

22

PubMed References

ClinicalTrials.govPubMed ESearchExact-name queryChecked May 3, 2026

Registered trials are ClinicalTrials.gov intervention records. Trial publications are PubMed records tagged as clinical trials or randomized controlled trials. PubMed references are broader source-query matches and can include animal studies, in-vitro work, reviews, mechanism papers, and trial publications.

27

Registered trials

0

Trial publications

0

RCT publications

22

PubMed references

4

Reviews

0

Meta-analyses

Registered trials source

Jun 1, 2026

Sermorelin

Uses the exact compound name as a ClinicalTrials.gov intervention query.

View source

Publication counts source

May 3, 2026

Sermorelin

Uses the exact display name.

View source

Previously FDA-approved (Geref, 1997). Branded product discontinued 2008 (manufacturing, not safety). Widely compounded. Potential Category 1 reinstatement under RFK announcement.

Key PubMed References

Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions.

Review

Rahman OF, Lee SJ, Seeds WA · Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2026

PMID: 41490200

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

Review

Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026

PMID: 41966639

Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

Animal Study

Uçaktürk E, Nemutlu E · Journal of pharmaceutical and biomedical analysis · 2026

PMID: 41138283

A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Review

Coutinho LFD, DE Oliveira Neves LF, Camilo RP · The Journal of sports medicine and physical fitness · 2026

PMID: 41880199

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Animal Study

Thomas A, Walpurgis K, Thevis M · Journal of mass spectrometry : JMS · 2024

PMID: 38197510

Anecdotes & Sentiment

Public discussion, not clinical evidence

This section summarizes what people are talking about in public sources. It can be useful for spotting questions, hype cycles, and recurring concerns, but it is separate from the evidence sections above.

mixedAnecdotalFeb 24, 2026

Clinic and wellness demand

Sermorelin is presented as one of the peptides with increased wellness-clinic demand, especially around muscle, aging, and energy narratives.

TIMEhigh confidencemedia
Source

Side Effects & Safety

- Injection site reactions (redness, swelling) - Facial flushing - Headache - Dizziness or lightheadedness

Injection site reactions (redness, swelling)
Facial flushing
Headache
Dizziness or lightheadedness

Known Interactions

No curated interaction entry is live for Sermorelin yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Regulatory status can vary by compound, formulation, indication, and jurisdiction. Check official labeling, registry records, and qualified professional guidance before making any health-related decision. The studies referenced are linked to their original PubMed sources for verification.